U.S. and Europe First in Line to Get Pfizer Covid Vaccine
- Pfizer, BioNTech will split small stock ‘in a fair fashion’
- Drugmakers’ vaccine stops 90% of infections in study
This article is for subscribers only.
The U.S. and Europe are in line to get the first doses of an experimental coronavirus vaccine after a partnership between Pfizer Inc. and BioNTech SE delivered dazzling preliminary results in a large patient trial.
Regulators on both sides of the Atlantic ocean are working to speed a review of the shot’s safety and effectiveness after the data showed it prevented more than 90% of infections. Monday’s release placed the two drugmakers firmly in the lead of the vaccine race, ahead of Moderna Inc. and AstraZeneca Plc.